Programmatic implications for regular COVID boosters will be foremost on the agenda at an FDA advisory committee meeting on Wednesday, according to briefing documents released by agency staff.
At the April 6 meeting, FDA is asking its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to not only lay out parameters for how to determine when it might be necessary to update the composition of COVID boosters, but how often and how it might be applied to both approved and authorized vaccines.
